Clinical utilization of dual antiplatelet therapy (DAPT) in patients with renal impairment (RI) following percutaneous coronary interventions (PCI) represents an urgent, unmet need choosing optimal agents, duration of treatment, and potential dose/regimen adjustment. The lack of any large randomized trials specifically in RI patients, and the absence of the uniformed clinical data reporting policy, clouds the reality. Moreover, triaging RI patients is problematic due to ongoing kidney deterioration, and the fact that RI patients are prone to both vascular occlusions and bleeding.
Introduction
Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is currently a standard care for reducing thrombotic ischaemic events in patients after percutaneous coronary intervention (PCI). 1, 2 However, despite significant improvement of cardiovascular outcomes, residual thrombotic risk remains disproportionately high in patients with renal impairment (RI). 3, 4 It is well established that RI affects outcomes following PCI; 5, 6 however, the impact of RI severity on occlusions or/and bleeding is still controversial. 7, 8 In fact, our inability to assess adequately the clinical outcomes during DAPT in RI patients has been well recognized. 9, 10 Most of the evidence assessing DAPT in RI patients consists of subgroup analyses of trials, which excluded patients with severe RI. Not only the sample sizes of most RI subgroups are woefully small, but also the definitions of RI are variable making cross-trial comparisons and definite conclusions difficult. In addition, many trials deliberately avoided enrolling RI patients, especially those with end-stage renal failure, requiring dialysis or/and kidney transplantation. Finally, the problem that RI patients are simultaneously prone to both thrombotic vascular occlusions and excess bleeding risks, what makes the task of finding an optimal DAPT regimen a variation of 'mission impossible' for this high-risk population. Therefore, an optimal use of antiplatelet agents in RI patients is not yet well defined. This obvious obstacle was confirmed in a Cochrane meta-analysis of 50 studies, which enrolled 27 139 participants, suggesting that antiplatelet agents reduce myocardial infarction but increase major bleeding. 11 The aim of this study was to assess residual platelet reactivity during chronic DAPT dependent on gradual triaging of RI stage with adverse clinical outcomes in a large cohort of post-PCI Korean patients.
Methods Patients
This was a single centre prospective observational study conducted at the Cardiology Institute of Dong-A University Hospital (Busan, Korea). Written informed consent was obtained from all patients, and the study protocol was approved by the Institutional Review Board of Dong-A University Hospital. From March 2010 to March 2015, we enrolled 701 consecutive PCI-treated patients receiving maintenance DAPT (75 mg/day clopidogrel and 100 mg aspirin). Patients ≥18 years of age who had undergone drug-eluting stent implantation without exclusion criteria were included. Exclusion criteria were as follows: clopidogrel and aspirin maintenance duration ,1 month, haemodynamic instability, malignancies, active bleeding or bleeding diathesis, contraindication to antiplatelet agents, concomitant use of warfarin or glycoprotein IIb/IIIa receptor blocker, platelet count ,80 000/mm 3 or haematocrit ,30%, an aspartate aminotransferase concentration or an alanine aminotransferase (ALT) concentration ≥3 times the upper normal limit, significant hepatic dysfunction, a treatment with ticlopidine, prasugrel, ticagrelor, dipyridamole, cardiac arrest, and cerebrovascular injury with 3 months. The RI was defined according to the United States National Kidney Foundation classification as follows: kidney damage with normal or increased glomerular filtration rate (GFR; creatinine clearance ≥90 mL/ min), mild reduction in GFR (creatinine clearance 60 -89 mL/min), moderate reduction in GFR (creatinine clearance 30 -59 mL/min), and severe reduction in GFR or kidney failure (creatinine clearance ,30 mL/min). 12 The estimated GFR (eGFR) is reported per mL/min/ 1.73 mm 2 . In the present analysis, patients were first categorized into five groups according to the renal functions: normal (RI1, or reference), mild (RI2), moderate (RI3), severe or kidney failure (RI4), and dialysis (RI5).
Clinical outcomes
The major adverse clinical events (MACEs) were collected after 1-year follow-up. The composite MACE consisted of death from a cardiovascular cause, MI, stent thrombosis, and stroke (ischaemic and haemorrhagic).
Clinically relevant bleeding complications were recorded by BARC type ≥2 scale 13 within 1 year of follow-up.
Platelet reactivity
The tests were performed at 1 month following enrolment simultaneously with eGFR calculation. Blood was drawn between 4 and 12 h after last administration of routine medications including clopidogrel and aspirin to reduce the variability during the loading phase. Platelet function was assessed with VerifyNow P2Y12 assay (Accumetrics, San Diego, CA, USA). The assay is a whole-blood, cartridge-based, optical detection system designed to measure platelet aggregation. Blood was drawn into a Greiner Bio-One 3.2% citrate Vacuette tube (Greiner Bio-One, Monroe, NC, USA). The ADP P2Y12 receptor is measured in a cartridge channel of the VerifyNow P2Y12 assay containing ADP, a platelet agonist, and prostaglandin E1, a suppressor of intracellular-free calcium levels, which reduces the non-specific contribution of ADP binding to P2Y1 receptors. The platelet responses were expressed in P2Y12 reaction units (PRU). 
Statistical analysis

Results
Study population
A total of 701 patients were categorized into five groups according to renal function. One hundred and twenty-three patients (17.5%) with RI1, 345 patients (49.2%) constituted RI2, 187 patients (26.7%) with RI3, 35 patients (5.0%) with RI4, and 11 patients (1.6%) undergoing dialysis (RI5). The baseline demographics and clinical characteristics of the study participants are summarized in Figure 1 .
Adverse outcomes
There were 27 MACEs (7 CV deaths, 3 MIs, 9 stent thrombosis, and 8 strokes) over 1-year follow-up. The distribution of MACE dependent on eGFR is presented in Table 2 . Deaths occurred exclusively in RI3 -5 subgroups. Among seven fatalities, one patient exhibit low platelet reactivity, three heightened, and three average response after DAPT. All three MIs were reported in an RI2 group. Stent thrombosis and strokes were distributed fairly even. In addition to exploring the relationship between the platelet activity and eGFR, the potential link between eGFR and MACE was evaluated. Lower eGFR demonstrated a significantly higher incidence of MACE as outlined in a Kaplan -Meier analysis (RI1 vs. RI2 vs. RI3 vs. RI4 vs. RI5; 0.8 vs. 2.7 vs. 3.3 vs. 14.5 vs. 36.6%, P , 0.001, Figure 2 ). The incidence of bleeding at 1 year dependent on renal function was low. There was a slight trend (P ¼ 0.143) towards excess bleeding in RI4; however, the numbers are woefully small to draw any definite conclusions, or propose associations. The distribution of the bleeding events dependent on RI is presented in Table 3 . The distribution of bleeding events was unremarkable potentially due to the low sample size in RI3 -RI4 cohorts. Most events occur late after DAPT initiation, and were of mild severity (BARC scale 3), predominantly of gastrointestinal origin. As indicated in Table 4 , the risk for MACE increased greatly especially for RI4 -RI5. The cumulative multivariate Cox hazard regression estimates for MACE and combination of MACE and bleeding events are presented in Tables 5 and 6 . While bleeding risks suggest no association with RI, severe decline in eGFR (RI4 and RI5) was significantly linked to thrombotic secondary MACE rates.
Discussion
Our study is the first to show that applying established conventional platelet test, namely VerifyNow TM Analyzer at the maintenancephase DAPT, may distinguish gradual deterioration of renal function and predict associated MACE. Deterioration of eGFR is strongly linked to enhanced platelet activity during DAPT. There are few important confirmations to be made. First and upmost important, patients with even mild RI experience much more frequent vascular thrombotic events than those with normal kidney function. Needless to say that RI4 and patients on dialyses (RI5) were at the highest risk, suggesting DAPT inadequacy at least in some patients. This disturbing finding raises obvious concerns that we should consider antiplatelet dose/regimen adjustments in RI patients, the strategy which is currently not recommended by the FDA. The problem is that RI patients constitute no more than 10-15% of the entire antiplatelet trial pool generating woefully small dataset(s) for each particular antiplatelet agent. Dichotomizing patients further into severe, mild, or moderate RI, makes such groups very small, usually in double-digit numbers hence preventing quality analyses. These circumstances allow the regulatory authorities to ignore such obvious shortcomings, or/and demand unbiased risk assessment in RI patients receiving DAPT. In short, there is something profoundly 
Continuous data are shown as mean + SD, and dichotomous data are shown as numbers (%). RI, renal impairment; BMI, body mass index. Dual antiplatelet therapy in renal impairment wrong in applying identical DAPT strategies after PCI in RI patients so vulnerable for bleeding, and diabetics with normal glomerular filtration, where platelets are so hard to inhibit. Indeed, there are numerous different platelet reactivity assays, which are available nowadays. However, platelet reactivity assessed by such different assays leads to contradictory results, for the same patient, at the same evaluation time, treated with the same DAPT regimen. We applied the VerifyNow test since it is pretty simple, fast, and do not require special blood sample preparation. Expressing digital result in PRU is also an objective advantage of the instrument. Regarding the impact of antiplatelet agents on efficacy, the scant evidence suggests some positive efficacy for reduction of myocardial infarction risks, but with uncertain effects on mortality, and consistently increased bleeding rates over diminishing eGFR. Furthermore, definitions of events are constantly changing especially with respect to bleeding, with rates varying greatly depending on the scales used. In addition, study durations and follow-up lengths are heterogeneous, making the comparisons even more challenging. Most reports suggest that the benefits of antiplatelet therapy in RI are uncertain and may be potentially outweighed by bleeding hazards, while acknowledging several serious gaps in evidence, 3 -11 especially the lack of randomized data. In short, managing DAPT in such highrisk population is complex because RI patients experience increased platelet activation but attenuated response compared with patients without RI, 14 even despite higher dosages. 15 Surprisingly, despite representing a cornerstone of modern DAPT, major clopidogrel trials are almost completely void of any references to RI. The CAPRIE publication mentions severe renal insufficiency as a contraindication for patient enrolment, 16 while diabetic nephropathy was one of the cardiac risk factors used for eligibility in CHARISMA. 17 None of the main publications for any clopdogrel trials provide RI subgroup analyses or mention renal-related adverse events. Later, the CURE secondary analyses revealed that even mild RI worsens the prognosis in patients with non-ST-elevation acute coronary syndromes. 18 Indeed, the CURE primary outcome (cardiovascular death, myocardial infarction, and stroke combined) occurred more frequently in the lowest GFR tertile. The bleeding risk was also significantly increased in these patients. 18 Importantly, patients with mild and moderate RI did not have a significant difference in outcomes with clopidogrel therapy vs. placebo (mild: 12.8 vs. 10.3%, P ¼ 0.30; moderate: 13.1 vs. 17.8%, P ¼ 0.24) in CRE-DO. 19 Clopidogrel use was associated with the moderate increased relative risk of major or minor bleeding, but this increased risk was not different based on renal function impairment (RR ¼ 1.2, 1.3, 1.1). In CLARITY, the risks of the primary endpoints, which included occlusion of the infarct-related artery on angiography as well as revascularization and cardiac events, and bleeding increased with declining renal function. 20 However, the benefit of clopidogrel was attenuated in patients with moderate renal dysfunction (HR 1.0 compared with about 0.6 in normal function and mild dysfunction, interaction P ¼ 0.9). 20 Unfortunately, the original FDA approval for clopidogrel in 1997, and further labelling changes did not analyse RI. This omission occurred despite the clinical pharmacology reviewer's evaluation in RI patients as inadequate because of the lack of a normal control group and concluding that a recommendation regarding dosage adjustment in RI patients could not be made unless adequate data were available in the clinical trial population. The pharmacology review did note that RI patients showed low (25%) inhibition of ADP-induced platelet aggregation. A major limitation is that the active metabolite of clopidogrel was not known in 1997 and hence not studied. Despite these inadequacies, the original label noted the low inhibition but concluded that 'No dosage adjustment is needed in RI patients'. The later FDA submissions and reviews add little regarding RI. The 2002 CURE review did not analyse efficacy relative to RI. Regarding bleeding, it merely mentioned a sponsor analysis that there was no significant interaction between clopidogrel and abnormal baseline renal function without providing the statistics. The additional 2006 review of the COMMIT and CLARITY studies tabulates a few renal failure adverse events and deaths, but they were rare enough that between arm comparisons were not informative. The review does not otherwise mention RI. From 1997 to 2015, the US clopidogrel label changed minimally with regard to RI: an adverse reaction of 'Increased creatinine levels' was added based on post-marketing experience. The section describing the pharmacokinetic study in RI patients was cut back and the following vague disclaimer added: 'Experience is limited in patients with severe and moderate RI'. Importantly, some evidence suggests that clopidogrel may not be ideal for patients with moderate RI, given the increased bleeding risk and the possibility of reduced efficacy. We can only speculate whether these adverse trends with decreasing renal function apply to patients with severe RI. It is disconcerting that, for a drug in widespread clinical use for nearly 20 years, its labelling provides no guidance on treating RI patients who comprise a sizable minority of the indicated populations. While some clinical outcomes data in RI patients are available for prasugrel, the numbers of RI patients exposed are too few to have absolute confidence in the results. The available data do not prove any differences in efficacy or safety for the RI patients than for patients with normal renal function. 21 Some indirect comparisons suggest that prasugrel and vorapaxar, but not ticagrelor, may perform better for both efficacy and bleeding than clopidogrel in RI patients. 22 Indeed, most likely, current DAPT recommendations are not written in stone, and impact of RI on adverse outcomes may yield serious changes in how we treat such patients in the future. 23 -26 Moreover, recent elegant analyses of ADAPT-DES registry, which included 8582 patients, suggested that heightened platelet reactivity in RI patients is linked to both ischaemic and bleeding events. 27 These data are in agreement with the index thrombotic MACE distribution dependent on RI, but not for bleeding, since our numbers were low. Finally, further research should focus on the role of proliferating vascular smooth muscle cells and endothelial cells during DAPT following PCI. 28 Indeed, the observed changes in residual platelet reactivity may be triggered by the underlying endothelial dysfunction rather than by RI per se.
Strengths and limitations
We deliberately triaged patients gradually with regard to RI, making five subgroups including patients on dialysis suitable for separate more precise analyses. In contrast, many papers define RI as eGFR ,60 per mL/min/1.73 mm 2 (ref. 5, 9, 13, 14) minimizing the comparisons, and leaving a lot of room for speculating on even slight changes in RI, and how it impacts residual platelet reactivity during DAPT. Also, the sample size of the index study was relatively large, comparable with other reports, 6, 9 and much larger (ref. 7, 8, 10, 13, 14) than other reports. Importantly, we measured platelet reactivity and eGFR at the same time, namely 1 month after DAPT start reassuring the unbiased analyses of the potential link between RI and platelet function. There are definite inherent limitations, which may influence the index results due to confounding factors. First, our cohort of patients was small, especially when considering the duration of enrolment, that is, 701 coronary interventions during 5 years, representing about 140 patients treated per year, which is lower than usually accepted recommendations. Also, the patients were not randomized, although the study was prospectively designed with the long follow-up. Secondly, a relatively small number of patients constituted the severe RI and especially woefully small in the dialysis group. Thirdly, platelet activity has been assessed only once with a single test, although we deliberately delayed the testing until 1 month at the DAPT maintenance phase. Fourthly, we have no proof that compliance to DAPT was good, since we did not measure clopidogrel active metabolite, or assess arachidonic acid-induced aggregation indicative of antiplatelet potency of aspirin. Fifthly, any mechanistic explanation, or even a hint, is lacking in the index study. Most definitely, the role of endothelial dysfunction, and haemostasis in general during RI should be better elucidated, since platelet activity impairment may be secondary to more general pathological mechanism. Finally, our study was done exclusively in patients of Korean origin with distinct genetic features potentially impacting drug metabolism, and responses after DAPT. Therefore, the extrapolation of these data for the European scenarios should be used with caution. We conclude that RI is associated with a gradual increase in residual platelet reactivity following DAPT, and elevated MACE risks. These data are still uncertain, and should be confirmed in a large randomized outcome-driven trial, potentially justifying future maintenance-phase DAPT regimen/dose adjustment in RI patients.
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